Advertisement
YOU ARE HERE: LAT HomeCollectionsVaccines
IN THE NEWS

Vaccines

SCIENCE
October 18, 2007 | Thomas H. Maugh II, Times Staff Writer
An experimental malaria vaccine protected 65% of Mozambique infants who received a full course of injections, paving the way for a large clinical trial of what could be the first vaccine against the deadly disease, researchers reported Wednesday. Infants are among the most vulnerable to malaria. Immunization of infants has proved difficult for a variety of illnesses, including measles and pneumococcal disease.
Advertisement
SCIENCE
December 23, 2009 | By Thomas H. Maugh II
Vaccine maker MedImmune has voluntarily recalled 13 lots of vaccine against the pandemic H1N1 influenza because they have lost some potency since they were manufactured, the company said Tuesday. "This is not a safety issue," Norman Baylor, director of the Office of Vaccines Research and Review at the Food and Drug Administration, said in a conference call. "All lots passed pre-release testing for safety, purity and potency. There has just been a slight decrease in potency." The 13 lots recalled involved 4.7 million doses of the intranasal vaccine, which is based on a live, weakened virus, but officials believe most of them were administered in October and November when the product would have still been at full potency.
SCIENCE
December 16, 2009 | By Thomas H. Maugh II
Vaccine manufacturer Sanofi-Aventis is recalling 800,000 doses of H1N1 vaccine meant for children younger than 3 because the influenza vaccine has lost potency since it was shipped from the factory. "This is non-safety-related, but is part of a routine quality assurance program," Dr. Anne Schuchat, director of the Centers for Disease Control and Prevention's National Center for Immunization and Respiratory Diseases, said in a telephone interview Tuesday. There are now 94.6 million doses of vaccine available, "so this is not as big a deal as it might have been earlier," she said.
SCIENCE
March 3, 2007 | From Times Wire Reports
The U.S. Army has carried out a promising early test of the first vaccine against hepatitis E, a form of the liver-attacking disease that sickens many Asians and can spread to soldiers or other Western visitors. The vaccine was 96% effective for Nepalese army soldiers who took all three doses, according to the New England Journal of Medicine.
SCIENCE
February 4, 2006 | From Times Staff and Wire Reports
Initial human tests indicate that an experimental vaccine for ricin works and is safe, raising the possibility that the vaccine might one day offer protection from the toxin, which authorities fear could be used as a terrorist weapon.
CALIFORNIA | LOCAL
February 29, 1988 | Compiled from Times staff and wire reports
The vaccine committee of the American Academy of Pediatrics has lowered the recommended age at which children should be vaccinated against Haemophilus influenzae type B, a bacteria that can cause meningitis, pneumonia, earaches and sore throats. The academy advised that 18-month-olds, especially those at high risk for infection because they are in day-care centers, now receive the so-called HiB vaccine. Previously, the pediatricians had only been recommending the vaccine for
CALIFORNIA | LOCAL
May 8, 1987 | From Reuters
One million doses of yellow fever vaccine arrived Thursday in Lagos to help combat an outbreak of the disease in western Nigeria that has claimed 140 lives, an aid official said.
NATIONAL
July 18, 2008 | From Times Wire Reports
Plans for a large-scale trial of a potential AIDS vaccine are being dropped in favor of a smaller, more focused study, the National Institutes of Health said. The trial of the vaccine, developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Disease, had been planned to include 2,400 men in the United States. However, the agency said it decided that the vaccine did not warrant a trial of that size and scope. The agency will plan a smaller, more focused clinical trial to test the vaccine's effectiveness.
NEWS
January 15, 1999 | From Times Wire Reports
A vaccine that attacks HIV at a vulnerable moment of the deadly virus' infection cycle has been shown to be effective in laboratory tests, researchers say. In studies at the University of Montana, researchers developed antibodies in mice that attacked HIV, the virus that causes AIDS, just as the virus was in the process of fusing with target cells. A report on the study is being published today in the journal Science.
NEWS
March 25, 1999 | Reuters
Researchers said Wednesday that they have used DNA from the parasite that causes malaria to produce a vaccine that they hope will prevent the disease. The new vaccine uses bits of the DNA to stop the parasite's growth in the bloodstream and should stop transmission of the infection, the researchers at the Johns Hopkins School of Public Health in Baltimore said. They wrote about their discovery in the April issue of the journal Infection and Immunity.
Los Angeles Times Articles
|